Fig. 5: Western blot analysis of mBDNF, TrkB and AKT in the PFC of WT and Fmr1-Δexon 8 rats following repeated oral psilocybin treatment. | Neuropsychopharmacology

Fig. 5: Western blot analysis of mBDNF, TrkB and AKT in the PFC of WT and Fmr1-Δexon 8 rats following repeated oral psilocybin treatment.

From: Psilocybin improves novel object recognition in a rat model of Fragile X Syndrome through the modulation of the BDNF/TrkB signaling pathway

Fig. 5: Western blot analysis of mBDNF, TrkB and AKT in the PFC of WT and Fmr1-Δexon 8 rats following repeated oral psilocybin treatment.

A mBDNF; B TrkB; C phosphorylated AKT (pAKTS473); D total AKT; E pAKT S473/AKT ratio measured in the whole homogenate of the PFC. Each sample was analyzed in duplicate gels, and results were averaged after correction for inter-gel variability. Densitometric values were normalized to β-actin and expressed as a percentage relative to vehicle-treated controls (WT-VEH). F shows representative immunoblots for TrkB (140 kDa), pAkt (ser473) and Akt (60 kDa), β-actin (43 kDa) and mBDNF (14 kDa). (WT-VEH = 5, Fmr1-Δexon 8-VEH = 5, WT-PSY = 5, Fmr1-Δexon 8-PSY = 5). Data represent means ± SEM, *p < 0.05, **p < 0.01 and ***p < 0.001 vs WT-VEH group; #p < 0.05, ##p < 0.01 vs Fmr1-Δexon 8-VEH group (two-way ANOVA followed by Tukey’s post hoc test).

Back to article page